---
title: Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells
  for cancer therapy research
date: '2025-01-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39824562/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Treatment with autologous chimeric antigen receptor (CAR)-modified T
  cells can achieve outstanding clinical response rates in heavily pretreated patients
  with B and plasma cell malignancies. However, relapses occur, and they limit the
  efficacy of this promising treatment approach. The complex GMP-compliant production
  and high treatment costs cause that CAR T cells cannot yet be used in a broad population.
  Among others, CAR T cell therapy has evolved regarding vector design and ...
disable_comments: true
---
Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production and high treatment costs cause that CAR T cells cannot yet be used in a broad population. Among others, CAR T cell therapy has evolved regarding vector design and ...